What informed consent must cover for peptides, common malpractice vectors, and how documentation protects against liability.
The Consent Form That Costs You Everything A patient receives a peptide injection and develops an unexpected adverse reaction. She sues. In discovery, her lawyer asks: "Walk me through what the patient was told about this unapproved therapy before injection." If your answer is "we gave her a general informed consent form," you're about to have a very expensive conversation with your malpractice carrier. Informed consent for peptide therapy is not a checkbox. It's a documented conversation that proves you disclosed the key risks, alternatives, and unapproved status before your patient agreed to treatment. When disputes arise—and in an emerging field like peptide therapy, they will—that documentation becomes your only defense.
Legally adequate informed consent for unapproved peptide therapy requires disclosure of four elements:
1. Unapproved Status
Your patient needs to understand, explicitly, that the peptide they're receiving has not been approved by the FDA for their condition. This sounds obvious, but courts have found clinics negligent for burying this fact in fine print or using vague language like "investigational" without clarity.
Your consent form should say: "The peptides used in this protocol have not been approved by the FDA for the treatment of [condition]. We are using these compounds based on clinical evidence and research, not FDA approval."
This is not optional language. It's foundational.
2. Known Risks and Adverse Effects
Your patient must understand what could go wrong. Not theoretical risks—actual risks documented in the research literature or observed in clinical practice.
For peptides, this includes: injection-site reactions (pain, redness, swelling), systemic effects (nausea, headache, fatigue), potential for allergic reactions, and risks specific to the peptide being used. If you're using a multi-peptide protocol, each peptide's known risks should be listed.
You should also disclose unknown risks. Peptides are emerging therapies. You don't have decades of safety data. Your consent form should state: "Because these are relatively new compounds, long-term effects are not fully established."
3. Available Alternatives
The patient consented to peptide therapy. But did they know what other options existed? Traditional anti-aging interventions? Other longevity approaches? Different peptides?
Your consent form should list alternatives—even if they're less appealing to the patient. The legal standard is not "we picked the best option." It's "we told the patient what their options were, they understood them, and they chose this one anyway."
4. Specific Acknowledgment of Understanding
Don't assume consent. Document it. A robust consent process includes:
If possible, have the patient initial next to each major risk disclosure. This creates a paper trail showing they didn't just sign at the end without reading.
According to insurance data, peptide-related malpractice claims cluster around a few themes. Understanding them helps you bulletproof your consent process:
Adverse Reaction + No Warning = Negligence
A patient develops an adverse reaction and claims she was never told it was possible. Your defense hinges entirely on your consent documentation. If your form doesn't mention that specific reaction, or if you have no evidence the patient was informed, you lose.
Improper Dosage + Insufficient Monitoring
A patient claims you prescribed an unsafe dose or failed to adjust doses based on her response. Your documentation needs to show: dose rationale, monitoring plan, and adjustments made based on patient feedback or labs.
Failure to Obtain Informed Consent
This is the most common claim we see. The patient claims you didn't adequately disclose risks. Your written consent form is your only evidence that you did.
Inadequate Storage and Contaminated Product
If a peptide is improperly stored or sourced from an uncontrolled supplier and the patient is harmed, your lack of documentation about sourcing and storage becomes evidence of negligence.
Misleading Marketing and Off-Label Claims
If your marketing materials promise results the peptide cannot deliver—"will increase muscle by 15%" or "guaranteed fat loss"—and the patient doesn't see those results, you've exposed yourself to false advertising and malpractice claims.
A signed consent form is necessary but not sufficient. Here's what separates clinics that lose claims from clinics that defend them successfully:
Document the Conversation: If you have an in-person consultation with a patient, your notes should reflect the informed consent discussion. "Discussed risks of peptide therapy, patient understands unapproved status, questions answered" is minimal documentation, but it's better than nothing.
Tailor to the Protocol: A generic informed consent form for "peptide therapy" is weaker than protocol-specific forms. If you're using BPC-157, your consent should discuss BPC-157 specifically—its known effects, its known risks, why you selected it for this patient.
Update as Science Evolves: As new research emerges about a peptide, your consent form should evolve. If a study is published showing a new risk, you should update your forms and re-consent existing patients if the new risk is material.
Create a Consent Process, Not a Signature: The strongest defense isn't a form—it's evidence of a deliberate process. Did the patient complete a questionnaire? Did you have a consultation call? Did you provide educational materials? The more steps in your process, the harder it is for a patient to claim she was uninformed.
At minimum, your informed consent form should include:
This is not legal advice—consult an attorney licensed in your state—but it's the floor.
Every lawsuit costs money: defense costs, settlement/judgment costs, reputation damage, and increased insurance premiums. A clinic with strong informed consent documentation is less likely to face claims and far more likely to defend successfully if a claim does arise.
As the anti-aging drugs market grows from $19.18B in 2025 to a projected $58.43B by 2035, more patients will seek peptide therapy and more will expect results they may not achieve. Your informed consent documentation is what separates patient education from patient abandonment.
---
*This article is for informational and educational purposes only. It does not constitute medical, legal, or financial advice. Clinic operators should consult qualified legal counsel, compliance advisors, and medical boards for guidance specific to their practice and jurisdiction. MyProtocolStack is a protocol tracking and blood work analysis platform — it is not a medical device and does not provide clinical recommendations.*
Enter your blood work in MyProtocolStack, run StackAI analysis, and get personalized insights based on your actual numbers -- not generic charts.
Start Free →